Aglan

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

91 API Suppliers, 21 USDMF, 15 CEP/COS, 8 JDMF, 17 EU WC, 32 KDMF, 21 NDC API, 39 Listed Suppliers

DEVELOPMENTS

98 Drugs in Development

98 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

583 FDF Dossiers, 64 FDA Orange Book, 310 Europe, 36 Canada, 34 Australia, 44 South Africa, 95 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Evonik, 3 Rochem International Inc, 8 SPI Pharma, 8 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 7 Kirsch Pharma, 1 Panvo Organics, 2 Cerata Pharmaceuticals LLP, 8 Dr. Paul Lohmann GmbH & Co. KGaA, 4 ACG Worldwide, 7 Actylis, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 20 BASF, 1 CD Formulation, 7 DFE Pharma, 7 Gangwal Chemicals, 1 Gloria Interchem, 2 Ideal Cures, 4 Ingredion Pharma Solutions, 16 Kerry, 3 Keval Exports, 3 Lonza Capsugel, 12 Microlex e.U, 1 Nanjing Bold Chemical, 1 Neelkanth MineChem, 3 Nitika Pharmaceutical Specialities, 2 Novo Excipients, 5 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Pharmachem, 1 Qualicaps, 27 Roquette, 1 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 4 Silverline Chemicals, 2 Ulanqab Kema New Material, 4 Vasa Pharmachem, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

57 Fillers, Diluents & Binders, 39 Disintegrants & Superdisintegrants, 35 Direct Compression, 31 Granulation, 21 Lubricants & Glidants, 18 Thickeners and Stabilizers, 17 Taste Masking, 15 Chewable & Orodispersible Aids, 15 Parenteral, 14 Co-Processed Excipients, 13 Coating Systems & Additives, 12 Film Formers & Plasticizers, 11 Solubilizers, 11 Controlled & Modified Release, 10 API Stability Enhancers, 8 Empty Capsules, 6 Topical, 4 Emulsifying Agents, 2 Surfactant & Foaming Agents, 2 Rheology Modifiers, 1 Soft Gelatin

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 58 News #PharmaBuzz

GLOBAL SALES INFORMATION

16 US Medicaid Prescriptions, 27 Regulatory FDF Prices, 1 Annual Reports

MARKET PLACE

37 APIs, 2 FDF Dossiers, 1 Intermediates

PATENTS & EXCLUSIVITIES

81 US Patents, 4 US Exclusivities, 12 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 20 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

Xls

Filters

Aglan

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Looking for Aglan? Find Coloring Agents used in Aglan to address drug delivery challenges on PharmaCompass.

Aglan

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

91 API Suppliers

21 USDMF

15 CEP/COS

8 JDMF

17 EU WC

32 KDMF

21 NDC API

39 Listed Suppliers

DEVELOPMENTS

98 Drugs in Development

INTERMEDIATES

20 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

583 FDF Dossiers

64 FDA Orange Book

310 Europe

36 Canada

34 Australia

44 South Africa

95 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SUSPENSION;ORAL - 7.5MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem

1 Evonik

3 Rochem International Inc

8 SPI Pharma

8 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

7 Kirsch Pharma

1 Panvo Organics

2 Cerata Pharmaceuticals LLP

8 Dr. Paul Lohmann GmbH & Co. KGaA

4 ACG Worldwide

7 Actylis

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

20 BASF

1 CD Formulation

7 DFE Pharma

7 Gangwal Chemicals

1 Gloria Interchem

2 Ideal Cures

4 Ingredion Pharma Solutions

16 Kerry

3 Keval Exports

3 Lonza Capsugel

12 Microlex e.U

1 Nanjing Bold Chemical

1 Neelkanth MineChem

3 Nitika Pharmaceutical Specialities

2 Novo Excipients

5 Pharmatrans-Sanaq

6 Pluviaendo

4 Prachin Pharmachem

1 Qualicaps

27 Roquette

1 Seppic

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

4 Silverline Chemicals

2 Ulanqab Kema New Material

4 Vasa Pharmachem

2 Zhejiang Huakang Pharmaceutical

TABLET;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, ORALLY DISINTEGRATING;ORAL - 7.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons